logo-loader
viewClinigen Group PLC

Clinigen Group PLC to distribute Jazz Pharmaceuticals' leukaemia drug

Clinigen specialises in managed access programmes which provide medicines to people in need where the product does not have regulatory sign-off in the local jurisdiction

vials of blood
Vyxeos will be prescribed to patients aged 60-75 with newly-diagnosed therapy-related acute myeloid leukaemia

Clinigen Group PLC (LON:CLIN) has been appointed by US-listed drug developer Jazz Pharmaceuticals (NASDAQ:JAZZ) to provide access to the latter’s leukaemia treatment.

Clinigen specialises in managed access programmes which provide medicines to people in need where the product does not have regulatory sign-off in the local jurisdiction.

READ: Clinigen says recent purchases bedding well as it weighs in with solid first-half performance

The company will be the distributor for Vyxeos in the UK, Ireland, Germany, Poland, Belgium, Switzerland, Portugal, Spain and Canada.

Acute myeloid leukaemia

It will be prescribed to patients aged 60-75 with newly-diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes.

"There is a huge unmet need for adults with AML where treatment options to date have been very few,” said John Lagus, head of managed access at Clinigen.

“Vyxeos provides the first FDA approved chemotherapy treatment for patients with certain types of high-risk AML in more than 40 years."

Quick facts: Clinigen Group PLC

Price: 865.5 GBX

AIM:CLIN
Market: AIM
Market Cap: £1.15 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Clinigen Group PLC named herein, including the promotion by the Company of Clinigen Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Clinigen Group reports on 'transformational' year with strong profit growth

Clinigen Group PLC's (LON:CLIN) head of investor relations Matt Parrish caught up with Proactive London's Andrew Scott following the release of the firm's results for the year to June 2019. The firm's gross profit was up 30% at £182.3mln, while revenues were ahead 20% at £456.9mln. Underlying...

on 19/9/19

2 min read